RxDoctor Payments Data

Joshua Bloomberg, DO

Internal Medicine · Tempe, AZNPI 1881966448

Payments from drug & device makers

$8,418in general payments, 2019–2025

Across 473 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • AstraZeneca$718
  • Amgen$561
  • Abbott$537
  • Pfizer$526
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$8,379100%
  • Education$390%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,418 in reported general payments places this provider in the 90th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$268,578
Medicare patients
315
Services billed
6,687

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide109$148,269
EliquisApixaban101$98,856
FarxigaDapagliflozin Propanediol71$75,772
TrulicityDulaglutide55$74,370
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf12$59,693
MounjaroTirzepatide36$47,999
MyrbetriqMirabegron29$23,515
JardianceEmpagliflozin13$20,338
Tresiba Flextouch U-200Insulin Degludec15$20,083
RybelsusSemaglutide11$19,069
Repatha SureclickEvolocumab18$18,905
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$17,311
Tresiba Flextouch U-100Insulin Degludec20$17,282
Breo ElliptaFluticasone/Vilanterol21$14,973
Praluent PenAlirocumab11$14,513

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,124$167,338120 claims
Lilly USA, LLCTrulicity, Mounjaro$304$122,36991 claims
PfizerEliquis, Paxlovid$526$100,224150 claims
AstraZenecaFarxiga, Symbicort$718$86,998101 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$371$39,45364 claims
Astellas Pharma US IncMyrbetriq$69$23,51529 claims
Boehringer IngelheimJardiance$192$20,33813 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$3,689283 claims
AbbVieSynthroid$1,360$1,81527 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Tempe

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →